NOCEBO Effect

We all are aware of the term PLACEBO..But for some this NOCEBO might be new..

The term nocebo (Latin for "I will harm") was chosen by Walter Kennedy, in 1961, to denote the counterpart of one of the more recent applications of the term "placebo" (= "I will please"); namely, that of a placebo being a drug that produced a beneficial, healthy, pleasant, or desirable consequence in a subject, as a direct result of that subject's beliefs and expectations.

Today, in the same way that the term placebo (or "placebo drug") is often used wrongly in an agent-oriented way to denote an active drug that produces an entirely predictable, and intentionally sought after outcome that is experienced as pleasant or desirable (e.g., analgesia), the term nocebo (or nocebo drug) is often used wrongly to denote its counterpart, an active drug that produces an entirely predictable, and intentionally sought outcome that is experienced as unpleasant or undesirable (e.g., nausea).

The nocebo response

If people expect to feel better from a pill or medical treatment, they just might, even if the pill is made of sugar or the treatment is a sham. This kind of response is so well established that researchers regularly use placebos—inert or dummy drugs, classically described as “sugar pills”in clinical trials to help gauge how much of an active medication’s effectiveness comes from the drug itself.

But placebos have a flip side: some people claim to feel worse after taking the inert chemicals. They complain of headaches, fatigue, insomnia, stomach*aches, nausea, dizziness, weakness, and other symptoms—side effects they claim weren’t there, pre-placebo. These ailments are not only real, but can be disabling, and about a quarter of those taking placebos report them, says professor of psychiatry Arthur Barsky, who studies medically unexplained symptoms.

This puzzling phenomenon, the “nocebo” effect (in Latin, placebo means “I shall please,” and nocebo, “I shall harm”), occurs in large part because people re-label existing ailments as side effects of their medication, according to Barsky. If the effect accompanies dummy drugs, then it generally does the same with active ones. Hence, nocebo effects can contaminate clinical trials, because doctors may attribute to a drug negative side effects that are actually nocebo effects.

The issue is “very important clinically,” Barsky says, because nocebo effects can be distressing and costly. Patients who blame their symptoms on the pill they’re taking may give up too soon on a potentially beneficial treatment. They can also waste time and money by returning to the doctor to have the medication changed, or to seek treatment for their nocebo symptoms.

Nonspecific side effects simply add to the burden of a patient’s illness, and Barsky would like to see that change. But he admits it won’t be easy. “It can be very complicated to decide if any given symptom is directly related to the drug,” he says. In 2002, he and three colleagues published a literature review of nocebos in the Journal of the American Medical Association (JAMA). The paper cites a study of a commonly prescribed drug in which researchers were able to link only 11 percent of adverse side effects reported by patients directly to the medication—leaving the other 89 percent, potentially at least, in the nocebo category.

Nocebo symptoms are often vague. Many of us walk around daily feeling mild aches and pains that we mostly ignore. But add to the mix an illness and a prescription medication, and it’s easy to see how we might interpret our upset stomach or sleepiness as a side effect of the drug we’re on.

The JAMA paper cites other factors. A patient who expects to suffer painful symptoms is more likely to. Depressed patients tend to feel bodily distress. Women, who report disturbing initial symptoms more often than men, are also more likely to report nocebo effects. Patients with a history of side effects can become conditioned to develop them again—and not only because of drugs. In one study, a third of chemotherapy patients felt extremely nauseous upon entering a room painted the same color as the one where they got their chemo treatments.

External factors come into play as well. A drug’s reputation can make people wary. Many patients, for example, are aware of allergies to penicillin—up to 10 percent of those hospitalized report a penicillin allergy, according to Barsky’s paper. But in a carefully supervised and monitored study of such patients, 97 percent of them actually had no reaction when they were administered oral penicillin. Even a pill’s size, shape, and color can make a difference. Studies have shown that red, orange, and yellow pills are associated with stimulants; blue and green pills tend to make people sleepy.

Barsky’s research shows that about three-quarters of both patients and healthcare workers are unacquainted with the nocebo effect. He offers this advice to doctors and nurses: take pains to identify any chronic symptoms that patients may suffer from before beginning a course of treatment, and discuss the nocebo phenomenon with them. Admittedly, “It’s possible that some doctors will just switch the patient to another medication,” says Barsky. But they then risk seeing the same pattern of side effects repeat itself. In the long run, he says, they’ll save time by having these conversations.